Abstract
(Abstracted from Am J Obstet Gynecol 2020; doi: 10.1016/j.ajog.2020.11.034) The aim of this study was to improve the understanding among clinicians of uterine bleeding (UB) events requiring intervention among women treated with an oral anticoagulant (OAC) therapy. The authors examined the incidence of UB events in the US Food and Drug Administration's (FDA's) Sentinel System, a database that comprised medical encounter and outpatient pharmacy claims data contributed by 17 public and commercial health insurers and integrated delivery networks.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
